Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Hung Tseng and Jennifer Ku.
Hung Tseng
Connection Strength
6.066
Jennifer Ku
  1. Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults =65 Years of Age. Clin Infect Dis. 2024 Nov 22; 79(5):1283-1292.
    View in: PubMed
    Score: 0.996
  2. Effectiveness of a fourth dose of mRNA-1273 against COVID-19 among older adults in the United States: Interim results from an observational cohort study. Vaccine. 2023 06 29; 41(29):4212-4219.
    View in: PubMed
    Score: 0.900
  3. Vaccine effectiveness of the mRNA-1273 3-dose primary series against COVID-19 in an immunocompromised population: A prospective observational cohort study. Vaccine. 2023 06 01; 41(24):3636-3646.
    View in: PubMed
    Score: 0.894
  4. Risk of severe COVID-19 disease in individuals with Down syndrome: a matched cohort study from a large, integrated health care system. J Infect Dis. 2022 Jun 24.
    View in: PubMed
    Score: 0.843
  5. Natural Language Processing Versus Diagnosis Code-Based Methods for Postherpetic Neuralgia Identification: Algorithm Development and Validation. JMIR Med Inform. 2024 Sep 10; 12:e57949.
    View in: PubMed
    Score: 0.246
  6. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2335052.
    View in: PubMed
    Score: 0.238
  7. Real-world effectiveness of recombinant zoster vaccine in self-identified Chinese individuals aged =50 years in the United States. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2327145.
    View in: PubMed
    Score: 0.237
  8. mRNA-1273 bivalent (original and Omicron) COVID-19 vaccine effectiveness against COVID-19 outcomes in the United States. Nat Commun. 2023 09 20; 14(1):5851.
    View in: PubMed
    Score: 0.230
  9. Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults. Clin Infect Dis. 2023 01 13; 76(2):252-262.
    View in: PubMed
    Score: 0.219
  10. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun. 2023 Jan 12; 14(1):189.
    View in: PubMed
    Score: 0.219
  11. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):643-649.
    View in: PubMed
    Score: 0.218
  12. Author Correction: Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022 May; 28(5):1095.
    View in: PubMed
    Score: 0.209
  13. Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study. PLoS One. 2022; 17(4):e0267824.
    View in: PubMed
    Score: 0.208
  14. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022 Feb 21.
    View in: PubMed
    Score: 0.206
  15. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021 12 15; 375:e068848.
    View in: PubMed
    Score: 0.203

© 2024 Kaiser Permanente